Crucell licenses Isconova's adjuvant Matrix M for HIV and malaria vaccines
This article was originally published in Scrip
Executive Summary
Isconova has entered into an agreement granting Crucell the license to use its adjuvant Matrix M in HIV and malaria vaccines.